Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 15/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.59 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PTGFR | P43088 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983013 | 1.00 | PTGER3 (0.59) | PTGER3PTGER4PTGER1PTGER2DRD3 | |
| SCHEMBL2981086 | 0.84 | PTGER3 (0.70) | PTGER3PTGER4PTGER1PTGER2PTGDR | |
| SCHEMBL2981091 | 0.84 | PTGER3 (0.70) | PTGER3PTGER4PTGER1PTGER2PTGDR | |
| SCHEMBL2979455 | 0.83 | PTGER3 (0.79) | PTGER3PTGER4PTGER1PTGER2DRD3 | |
| SCHEMBL2979450 | 0.83 | PTGER3 (0.79) | PTGER3PTGER4PTGER1PTGER2DRD3 | |
| SCHEMBL2979950 | 0.81 | CYP2C9 (0.53) | PTGER3PTGER4PTGER1PTGER2DRD3 | |
| SCHEMBL2979949 | 0.81 | CYP2C9 (0.53) | PTGER3PTGER4PTGER1PTGER2DRD3 | |
| SCHEMBL2989559 | 0.76 | RAB9A (0.60) | PTGER3PTGER4PTGER2PTGDRTBXA2R | |
| SCHEMBL2971831 | 0.76 | PTGER3 (0.76) | PTGER3PTGER4PTGER1PTGER2DRD3 | |
| SCHEMBL2971837 | 0.76 | PTGER3 (0.76) | PTGER3PTGER4PTGER1PTGER2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | claimed |
| EP-1431267-A1 | CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | claimed |
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1431267-A1 | CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | PTGER2, PTGER4, PTGER1 | PTGER3 4/4885PTGER4 2/4885PTGER1 3/4885 |
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | PTGER2, PTGER4, PTGER1 | PTGER3 4/4885PTGER4 2/4885PTGER1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.